CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.94BCNY1.03B · vs all stocks (USD)
Revenue (TTM)
699.33MCNY104.00M · vs all stocks (USD)
Profit Margin
-3.93%vs Biotechnology peers
Beta
0.4650xvs all stocks
52-Week Change
-4.13%vs all stocks
Market Capitalization
6.94BCNY1.03B · vs all stocks (USD)
Enterprise Value
7.52BCNY1.12B · vs all stocks (USD)
Forward P/E
51.53xvs Biotechnology peers
Price to Sales (TTM)
9.92xvs Biotechnology peers
Price to Book (MRQ)
7.12xvs Biotechnology peers
Enterprise to Revenue
10.76xvs Biotechnology peers
Enterprise to EBITDA
90.63xvs Biotechnology peers
Gross Margin
67.52%vs Biotechnology peers
Profit Margin
-3.93%vs Biotechnology peers
Operating Margin
11.85%vs Biotechnology peers
Return on Assets (TTM)
0.93%vs Biotechnology peers
Return on Equity (TTM)
-0.31%vs Biotechnology peers
Revenue (TTM)
699.33MCNY104.00M · vs all stocks (USD)
Revenue per Share (TTM)
1.67CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-10.00%vs Biotechnology peers
Gross Profit (TTM)
460.79MCNY68.52M · vs all stocks (USD)
EBITDA (TTM)
50.81MCNY7.56M · vs all stocks (USD)
Net Income (TTM)
-27.51MCNY-4.09M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-51.20%vs Biotechnology peers
Operating Cash Flow (TTM)
-21.23MCNY-3.16M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-48.06MCNY-7.15M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
108.55MCNYFY2025 · Dec 31, 2025Revenue
719.17MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
238.82MCNYFY2025 · Dec 31, 2025Gross Profit
480.35MCNYFY2025 · Dec 31, 2025Operating Income
61.30MCNY9.12M · vs all stocks (USD)
Pre-tax Income
24.64MCNYFY2025 · Dec 31, 2025Income Tax Expense
16.56MCNYFY2025 · Dec 31, 2025Net Income
8.08MCNYFY2025 · Dec 31, 2025EBIT
40.26MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
94.58MCNYFY2025 · Dec 31, 2025Research & Development
87.37MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
221.18MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.84MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.19MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
15.62MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
8.08MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-27.62MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-15.08MCNYFY2025 · Dec 31, 2025Free Cash Flow
-58.93MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
365.20MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
8.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
20.78MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-24.12MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.83MCNYFY2025 · Dec 31, 2025Capital Expenditures
-43.85MCNYFY2025 · Dec 31, 2025Net Acquisitions
-5.04MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.25MCNYFY2025 · Dec 31, 2025Sale of Investments
1.51MCNYFY2025 · Dec 31, 2025Other Investing Activity
26.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-26.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
477.92MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-404.66MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.87MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.36MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
50.04MCNYFY2025 · Dec 31, 2025Shares Outstanding
420.78MSharesUpdated Aug 21, 2026Float Shares
208.39MSharesUpdated Aug 21, 2026% Held by Insiders
49.67%vs all stocks
% Held by Institutions
13.59%vs all stocks
Total Cash (MRQ)
534.06MCNY79.42M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.27CNYUpdated Aug 21, 2026Total Debt (MRQ)
719.92MCNY107.06M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6607xvs Biotechnology peers
Current Ratio (MRQ)
1.50xvs Biotechnology peers
Book Value per Share (MRQ)
2.32CNYUpdated Aug 21, 2026Total Assets
1.91BCNY284.42M · vs all stocks (USD)
Total Current Assets
938.74MCNYFY2025 · Dec 31, 2025Total Liabilities
839.37MCNYFY2025 · Dec 31, 2025Total Non-current Assets
973.86MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
130.16MCNYFY2025 · Dec 31, 2025Total Current Liabilities
709.21MCNYFY2025 · Dec 31, 2025Cash
365.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
371.16MCNYFY2025 · Dec 31, 2025Other Short-term Investments
80.19MCNYFY2025 · Dec 31, 2025Accounts Receivable
151.41MCNYFY2025 · Dec 31, 2025Inventory
259.49MCNYFY2025 · Dec 31, 2025Accounts Payable
92.77MCNYFY2025 · Dec 31, 2025Short-term Debt
483.75MCNYFY2025 · Dec 31, 2025Other Current Liabilities
9.51MCNYFY2025 · Dec 31, 2025Long-term Debt
75.40MCNYFY2025 · Dec 31, 2025Common Stock (Book)
420.78MCNYFY2025 · Dec 31, 2025Retained Earnings
-354.19MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.07BCNY159.60M · vs all stocks (USD)
52-Week Low
11.40CNYUpdated Aug 21, 202652-Week High
22.55CNYUpdated Aug 21, 202652-Week Change
-4.13%vs all stocks
Beta
0.4650xvs all stocks
50-Day MA
14.84CNYUpdated Aug 21, 2026200-Day MA
15.95CNYUpdated Aug 21, 2026Avg 10-Day Volume
12.05MSharesUpdated Aug 21, 2026Avg 30-Day Volume
13.43MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.0700CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.68Profit Margin: -0.04
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -1.10
Altman Z-Score 5.29: safe zoneNotable
Altman Z-Score: 5.29
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Animal Husbandry Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
Avalo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Edan Instruments Inc.
Tier 1ProductionApproval-Gated PipelineRule